Skip to main content

Articles

ASH 2018 - Chronic Lymphocytic Leukemia

ECOG-ACRIN Cancer Research Group: Phase 3 Study of Ibrutinib-Based Therapy in Untreated Younger Patients with CLL

ASH 2018 - Chronic Lymphocytic Leukemia

Prognostic Testing and Treatment Approaches in Patients with CLL: Interim Analysis of the informCLL Real-World Registry

ASH 2018 - Chronic Lymphocytic Leukemia

Acalabrutinib in Patients with Relapsed/Refractory and High-Risk, Treatment-Naïve CLL

ASH 2018 - Chronic Lymphocytic Leukemia

Frontline Ibrutinib Treatment Is Associated with Lower Total Cost of Care Compared with Chemoimmunotherapy in Patients with CLL

ASH 2018 - Chronic Lymphocytic Leukemia

Improved MRD Response Rates with Ibrutinib and Obinutuzumab in Patients with CLL

ASH 2018 - Chronic Lymphocytic Leukemia

MURANO Study Explores Potential for Venetoclax-Rituximab Combination Therapy in Relapsed/Refractory CLL

ASH 2018 - Chronic Lymphocytic Leukemia

Ibrutinib Treatment in Waldenström’s Macroglobulinemia: Follow-Up Efficacy and Safety from the iNNOVATE Study

ASH 2018 - Chronic Lymphocytic Leukemia

Dual Inhibition of Bruton’s Tyrosine Kinase and BCL2: A Promising Therapeutic Strategy for Myeloid and Lymphoid Leukemias

Original Research

Patient Preferences Associated with Therapies for Psoriatic Arthritis: A Conjoint Analysis

Yihua Xu, PhD; Lavanya Sudharshan, MS; Ming-Ann Hsu, MPH; Andrew S. Koenig, DO, FACR; Joseph C. Cappelleri, PhD, MPH, MS; Wen F. Liu, PharmD, BCPS; Timothy W. Smith; Margaret K. Pasquale, PhD

Stakeholder Perspective

Engaging Patients in Decision-Making for Psoriatic Arthritis Treatment

F. Randy Vogenberg, PhD, RPh

Practice Management

FDA Commissioner Outlines New Plan to Increase Biosimilars by Balancing Innovation and Competition

Eileen Koutnik-Fotopoulos

Page 62 of 244
Results 611 - 620 of 2434